Antibody formulation for the gastrointestinal tract

胃肠道抗体制剂

• 批准号: 517780-2017
• 负责人: Accili, Eric
• 金额: $ 0.91万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Engage Plus Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=640495
• 关键词: Antibody; formulation; gastrointestinal; tract

Salmonella infections represent a significant public health concern and disease burden. Significant sources ofinfection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofSalmonella infections in poultry products is one means to reduce human infections. While advances have beenmade in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressureon commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatcould be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestpoultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arebeing tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on theexpertise of Dr. Eric Accili in the fields of protein biochemistry and gastrointestinal (GI) tract biology. Thisproject proposes to develop antibody formulations appropriate for application in the GI tract. The developmentof a Salmonella-selective antibody that is highly effective in the GI tract would benefit Canadian and Worldpopulations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedby NovoBind in delivering this product would also be an economic boost to Canada.

沙门氏菌感染是一个重大的公共卫生问题和疾病负担。感染的主要来源通常是受污染的肉和家禽、蛋和新鲜农产品。因此，控制家禽产品中的沙门氏菌感染是减少人类感染的一种手段。虽然在减少加工家禽中沙门氏菌污染的频率方面取得了进展，但商业生产者在收获前生产设施中预防和/或消除这些病原体的压力越来越大。NovoBind Livestock Therapeutics Inc.提议开发一种新的基于抗体的治疗策略，可提供给商业种植者，以预防和/或消除收获前家禽生产设施中的沙门氏菌病原体。目前，已经产生了新的沙门氏菌特异性抗体，并正在使用体外和体内方法测试其有效性。本文提出的工作利用了Eric Accili博士在蛋白质生物化学和胃肠道生物学领域的专业知识。本项目拟开发适合胃肠道应用的抗体制剂。开发一种对胃肠道非常有效的沙门氏菌选择性抗体，将通过减少人类感染和疾病、生命损失和治疗费用，使加拿大和世界人口受益。NovoBind提供这种产品所产生的收入也将促进加拿大的经济发展。